Introduction
Inflammatory lung diseases refers to a group of diseases associated with various types and degrees of inflammatory cell accumulation in the lungs (Table  1) . Diseases typically included in this group are acute lung injury/acute respiratory distress syndrome (ALI/ARDS), idiopathic pulmonary fibrosis/usual interstitial pneumonia (IPF/UIP), nonspecific interstitial pneumonia, cryptogenic organizing pneumonia/bronchiolitis obliterans organizing pneumonia, collagen vascular disease-associated interstitial pneumonia, hypersensitivity pneumonitis/extrinsic allergic alveolitis, sarcoidosis, and eosinophilic pneumonia. In a broad sense, chronic obstructive pulmonary disease, bronchial asthma, and infectious diseases can also be included in this list.
Among these illnesses, ALI/ARDS is an acute-onset noncardiogenic or nonhydrostatic pulmonary edema, defined by a PaO 2 /FIO 2 ratio lower than 300 (ALI) and 200 (ARDS) 1) . ALI/ARDS is accompanied or caused by various illness and injuries (Table 2) 1,2) . Although its pathogenesis is largely undetermined, neutrophil-dominant acute inflammation and resultant tissue destruction are the main pathological features. Mortality associated with ALI/ARDS remains as high as 40%, and a novel therapy or therapies are eagerly desired 3) . In contrast, IPF/UIP is characterized by diffuse interstitial inflammation of mixed cell types, fibroblast proliferation, and accelerated remodeling of extracellular matrix, which results in irreversible destruction of the lungs 4) . The disease is progressive and often fatal with a mean survival of five years. Although several medications such as glucocorticoids, immunosuppressants, and pirfenidone have resulted in some improvement in a fraction of patients with IPF/UIP, there is no established treatment that reliably improves their prognosis.
Regenerative medicine has made drastic advancements during the last decade, and in addition to bone marrow-derived stem cells and progenitor cells, stem cells and progenitor cells in various organs and tissues have been identified. In the respiratory system, the discovery of several tissue stem cells and progenitor cells, and their roles under physiological and pathological conditions has been clarified. In this short review, lung tissue stem cells and progenitor cells, and their roles in inflammatory lung diseases are summarized. 
Lung Stem Cells and Progenitor Cells
In almost every organism, there exists a compensatory system or systems which replace damaged cells and tissues to maintain physiological functions.
Transdifferentiation of other types of differentiated cells and differentiation of stem cells and progenitor cells are the sources of newly generated cells and tissues, in addition to the proliferation of terminally differentiated cells. However, recent studies have revealed that the classical stem cell hierarchy, from stem cells through transient amplifying cells, to terminally differentiated cells, is not always retained, and terminally differentiated cells are capable of becoming facultative stem cells under certain conditions 5) . In the respiratory system, there exist several types of epithelial stem cells and progenitor cells, each of which is involved in tissue repair and regeneration at different levels of the bronchial tree. In the bronchioles of mice, Clara cells, which specifically express Clara cell-specific protein (CCSP), also called secretoglobin 1A1, CC10, or CCA, show characteristics of transient amplifying cells 6) . Stripp, et al. reported that naphthalene-resistant variant Clara cells located in bronchioalveolar duct junctions (BADJ) behave as stem cells 7) . In contrast, Kim et al. revealed that CCSP-and surfactant protein C-double-positive epithelial cells almost fully satisfy the phenotype of stem cells and they subsequently named these cells bronchioalveolar stem cells (BASC) 8) . They further showed that BASCs contribute to the repair of terminal bronchioles as well as alveoli. However, recent data do not support these findings 9) . In alveoli, alveolar epithelial type II cells can differentiate into alveolar epithelial type I cells and thus have been considered progenitor cells 10) . Among alveolar epithelial type II cells, a subgroup of E-cadherin-negative cells show high telomerase activity, high proliferative potential, and resistance to injurious stimuli, and thus are considered as lung stem cell or progenitor cell candidates 11) . On the other hand, CCSP-, SCA-1-, SSEA-1-, and Oct-4-positive cells separated from the lungs of newborn mice have recently been shown to be able to differentiate into alveolar epithelial type I and type II cells, and thus could also be lung stem cell or progenitor cell candidates 12) . These cells are also specifically infected and damaged by severe acute respiratory syndrome corona virus, suggesting targeted injury of lung stem cells and progenitor cells as a novel etiology for ALI/ARDS.
In addition to the findings in mice, isolation of human lung stem cells has recently been reported by several investigators. Tesei 16) . Even though lungs are severely damaged as a result of severe pneumonia or ALI/ARDS, lung function of affected patients can sometimes recover to almost normal levels. These findings strongly suggest the active participation of tissue recovery or regeneration mechanisms under these pathological conditions. Moreover, in patients with ALI/ARDS, the number of circulating EPCs was significantly increased, and their induction by some undetermined mediators is assumed [17] [18] . Furthermore, ALI patients with higher numbers of circulating EPCs had better prognoses, suggesting the contribution of EPCs to lung tissue repair in cases of ALI 18) . Engraftment of bone marrow-derived stem cells and progenitor cells into repaired lung tissue, and their participation in tissue repair has also been described using animal models of ALI/ARDS. Yamada et al. showed that lipopolysaccharide (LPS) administration induced emphysematous changes in the lungs of radiation-induced bone marrow-suppressed mice 19) . In a mouse model of pneumonia, lineage-negative bone marrow progenitor cells accumulated in the injured lungs 20) . In a rabbit model of oleic acid-induced ALI, intravascular administration of EPCs ameliorated lung injury 21) . Furthermore, intratracheal administration of MSCs was shown to ameliorate LPS-induced ALI 22) . However, differentiation of MSCs was not essential for therapeutic efficacy, and regulation of inflammation by MSC-derived humoral mediators was thought to be the major mechanisms of action 22) . In addition, a strategy to use MSCs as a gene vector is being considered 23) .
Tissue Stem Cells and Progenitor Cells in Inflammatory Lung Disease
Lung microvascular permeability is mainly regulated by alveolar epithelial cell plasticity, and its normalization is essential for recovery from ALI/ARDS. As mentioned previously, Kim et al. suggested the contribution of BASCs to the repair and regeneration of alveolar epithelial cells following lung injury. However, Rawlin et al. showed contradictory results using an animal model of hyperoxia-induced lung injury 9) . As the total number of BASCs was shown to be small, they do not seem to play a major role in the recovery of alveoli or terminal bronchioles 9, 24) . However, if we can find methods to actively increasing the number of BASCs, for example by regulating the Gata6-Wnt pathway, which was recently shown to be indispensable for the expansion of BASCs, they will become an attractive therapeutic target. Recently, human embryonic stem cell-derived alveolar epithelial type II cells were shown to abrogate ALI in mice 25) , revealing embryonic stem cells as candidates for the treatment of inflammatory lung diseases.
With regard to pulmonary fibrosis, epithelial cell injury was shown to induce fibrosis of the lungs 26) , and matrix metalloproteinases (MMPs), especially MMP-7, are known to be involved in this process 27) . The role of alveolar epithelial type II cells in lung tissue repair has been the focus of recent investigation once again, and intratracheal administration of isolated epithelial type II cells was shown to improve bleomycin-induced lung fibrosis in rats 28) . Intratracheal administration of bone marrow-derived lung epithelial progenitors and amniotic epithelial cells was also revealed to attenuate bleomycin-induced lung fibrosis in mice [29] [30] . Thus, cell therapy could be a promising approach even for IPF/UIP.
In addition to alveolar epithelial cells, vascular endothelial cell are another major target of extrinsic and intrinsic injurious stimuli. In fact, targeted deletion of forkhead box M1 (FoxM1) in endothelial cells, a key transcription factor involved inr cell proliferation, aggravated LPS-induced lung injury 31) . Accordingly, restoration of endothelial cells, in addition to alveolar epithelial cells, should be included in inflammatory lung disease treatment strategies.
Since the existence of tissue stem cells and progenitor cells in the lungs has been revealed, we are currently examining the mechanisms of tissue recovery and regeneration in mouse models of inflammatory lung diseases and in human lung tissues, using Musashi-1 as a marker of bronchiolar and alveolar epithelial stem cells and progenitor cells.
Concluding Remarks
It has become clear during the last decade that several types of tissue stem cells and progenitor cells exist at different levels of the bronchial tree and that bone marrow-derived stem cells are also capable of differentiating into lung epithelial cells. In various inflammatory lung diseases, stem cells and progenitor cells, derived from either bone marrow or lung tissue, are mobilized to injured lung tissues, and most likely contribute to the repair and regeneration of the tissue. In patients with severe lung dysfunction as a result of inflammatory lung diseases, intratracheal or intravascular administration of stem cells or progenitor cells could be a promising treatment approach. A potential alternative strategy is to administer endogenous or exogenous mediators that mobilize and activate these cells. Additional extensive research is necessary to actualize these concepts.
